

486. ACS Infect Dis. 2019 Aug 9;5(8):1433-1445. doi: 10.1021/acsinfecdis.9b00112. Epub
2019 Jun 11.

Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and
Nonreplicating Mycobacterium tuberculosis.

Lopez Quezada L(1), Li K(2), McDonald SL(2), Nguyen Q(2), Perkowski AJ(2), Pharr 
CW(2), Gold B(1), Roberts J(1), McAulay K(3)(4), Saito K(5), Somersan Karakaya
S(5), Javidnia PE(5), Porras de Francisco E(6), Amieva MM(6), Dı Az SP(6),
Mendoza Losana A(6), Zimmerman M(7), Liang HH(7), Zhang J(1), Dartois V(7), Sans 
S(8), Lagrange S(8), Goullieux L(8), Roubert C(8), Nathan C(1), Aubé J(2).

Author information: 
(1)Department of Microbiology and Immunology , Weill Cornell Medicine , 1300 York
Avenue , New York , New York 10065 , United States.
(2)Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of
Pharmacy , University of North Carolina at Chapel Hill , 125 Mason Farm Road ,
Chapel Hill , North Carolina 27599 , United States.
(3)Center for Global Health , Weill Cornell Medicine , 402 East 67th Street , New
York , New York 10065 , United States.
(4)Les Centres GHESKIO , 33, Boulevard Harry Truman , Port-au-Prince , Haiti.
(5)Department of Medicine , Weill Cornell Medical College , New York , New York
10065 , United States.
(6)Diseases of the Developing World (DDW), Tres Cantos Medicine Development
Campus , GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , Madrid 28760 , Spain.
(7)Public Health Research Institute, New Jersey Medical School , Rutgers, the
State University of New Jersey , 225 Warren Street , Newark , New Jersey 07013 , 
United States.
(8)Evotec ID (Lyon), SAS , 1541, Avenue Marcel Merieux , Marcy l'Etoile 69280 ,
France.

Erratum in
    ACS Infect Dis. 2019 Dec 13;5(12):2175.

The historical view of β-lactams as ineffective antimycobacterials has given way 
to growing interest in the activity of this class against Mycobacterium
tuberculosis (Mtb) in the presence of a β-lactamase inhibitor. However, most
antimycobacterial β-lactams kill Mtb only or best when the bacilli are
replicating. Here, a screen of 1904 β-lactams led to the identification of
cephalosporins substituted with a pyrithione moiety at C3' that are active
against Mtb under both replicating and nonreplicating conditions, neither
activity requiring a β-lactamase inhibitor. Studies showed that activity against 
nonreplicating Mtb required the in situ release of the pyrithione, independent of
the known class A β-lactamase, BlaC. In contrast, replicating Mtb could be killed
both by released pyrithione and by the parent β-lactam. Thus, the
antimycobacterial activity of pyrithione-containing cephalosporins arises from
two mechanisms that kill mycobacteria in different metabolic states.

DOI: 10.1021/acsinfecdis.9b00112 
PMCID: PMC7241432
PMID: 31184461  [Indexed for MEDLINE]

